Donor-derived stem cell memory CAR T cells show enhanced expansion and safety in post-HSCT relapse treatment
This first-in-human study (NCT01087294) investigates donor-derived CD19-CAR T cells for treating B cell malignancies relapsing after allogeneic hematopoietic stem cell transplantation. The key finding is that CAR-modified stem-cell memory T (TSCM) cells demonstrate significantly greater expansion and persistence compared to standard CAR T cells, enabling complete responses at low doses without requiring lymphodepletion. The therapy induced only mild cytokine-release syndrome dominated by IFN-γ, establishing TSCM cells as a robust and safe platform for next-generation CAR T cell therapy.
Key quotes
CAR-modified stem-cell memory T (TSCM) cells exhibited greater expansion and persistence than standard CAR T cells, enabling complete responses at low doses in the absence of lymphodepletion.
CAR TSCM cells induced mild cytokine-release syndrome, dominated by IFN-γ.
Their distinctive in vivo behavior and differentiation trajectory establish TSCM cells as a robust and safe platform for next-generation CAR T cell therapy.
Donor-derived CD8⁺ CAR TSCM cells exhibit enhanced expansion and a favorable safety profile, inducing complete responses at low doses without lymphodepletion.
From the article
You might also wanna read
A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers
Researchers developed an AI-driven framework for discovering CAR T cell therapy targets by integrating single-cell RNA sequencing data from
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
Antibody-ligand motif optimization enables multitarget switchable CAR-T therapy against solid tumors
This article presents a research study on optimizing a multitarget switchable CAR-T (sCAR-T) strategy to overcome antigenic heterogeneity an
Comments
Sign in to join the conversation.
No comments yet. Be the first.